2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. TAM Receptor
  5. Tyro3 Isoform
  6. Tyro3 Inhibitor

Tyro3 Inhibitor

Tyro3 Inhibitors (11):

Cat. No. Product Name Effect Purity
  • HY-12494
    LDC1267
    		Inhibitor 99.64%
    LDC1267 is a highly selective TAM (Tyro3, Axl and Mer) kinase inhibitor with IC50s of <5 nM/8 nM/29 nM for Tyro3,Axl and Mer respectively.
  • HY-12076
    BMS 777607
    		Inhibitor 99.36%
    BMS 777607 (BMS 817378) is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC50s of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, respectively, and 40-fold more selective for Met-related targets than Lck, VEGFR-2, and TrkA/B, with more than 500-fold greater selectivity versus all other receptor and non receptor kinases.
  • HY-117596
    UNC569
    		Inhibitor 99.92%
    UNC569 is a potent, reversible, ATP-competitive and orally active Mer kinase inhibitor with an IC50 of 2.9 nM and a Ki of 4.3 nM. UNC569 also inhibits Axl and Tyro3 with IC50s of 37 nM and 48 nM, respectively. UNC569 can be used for acute lymphoblastic leukemia (ALL) and atypical teratoid/rhabdoid tumors research
  • HY-114358
    Tamnorzatinib
    		Inhibitor 98.07%
    Tamnorzatinib (ONO-7475) is a potent, selective, and orally active Axl/Mer inhibitor with IC50 values of 0.7 nM and 1.0 nM, respectively. Tamnorzatinib sensitizes AXL-overexpressing EGFR-mutant NSCLC cells to the EGFR-TKIs, suppresses the emergence and maintenance of tolerant cells. Tamnorzatinib combines with Osimertinib (HY-15772) provides a bright promise for the study of EGFR-mutated non-small cell lung cancer (NSCLC).
  • HY-132200
    UNC5293
    		Inhibitor 99.93%
    UNC5293 is a MERTK-selective and potent inhibitor (Ki=190 pM). UNC5293 inhibits MERTK (IC50=0.9 nM) and is more selective over Axl, Tyro3 and Flt3. UNC5293 exhibits excellent mouse PK properties and is used for bone marrow leukemia research.
  • HY-173268
    UNC9426
    		Inhibitor
    UNC9426 (compound 12) is a potent, orally bioavailable and specific TYRO3 inhibitor with an IC50 of 2.1 nM. UNC9426 reduces platelet aggregation without increasing bleeding time. UNC9426 blocks TYRO3-dependent functions in tumor cells and macrophages.
  • HY-173400
    UNC8212
    		Inhibitor
    UNC8212 is a TAM kinase inhibitor. UNC8212 has potent inhibitory activity against MERTK and AXL (IC50: 1.5 nM and 1.3 nM, respectively), and also inhibits TYRO3 (IC50: 6.7 nM). UNC8212 mediates polypharmacological properties by targeting the structurally diverse "back pocket" region of the TAM kinase family. UNC8212 binds tightly to TAM kinases and potently inhibits MERTK and AXL phosphorylation. UNC8212 has anti-tumor effects and can be used in cancer immunotherapy and tumor cell targeting research.
  • HY-117548
    UNC1062
    		Inhibitor 98.92%
    UNC1062 is a MERTK-selective tyrosine kinase inhibitor, reduces activation of MERTK-mediated downstream signaling, induces apoptosis in culture, reduces colony formation in soft agar, and inhibits invasion of melanoma cells. UNC1062 potently inhibits MERTK kinase activity (MERTK IC50=1.1 nM, Morrison Ki=0.33 nM) and exhibits specificity within the TAM family (TYRO3 IC50=60 nM, AXL IC50=85 nM).
  • HY-124502
    UNC4203
    		Inhibitor 99.80%
    UNC4203 is a potent, orally available and highly selective MERTK inhibitor, with IC50s of 1.2 nM, 140 nM, 42 nM and 90 nM for MERTK, AXL, TYRO3 and FLT3, respectively.
  • HY-147218
    PF-07265807
    		Inhibitor
    PF-07265807 is a potent TAM and c-Met kinase inhibitor with IC50 values of 6.1 nM, 13.2 nM and 21.6 nM for AXL, MER and TYRO3, respectively. PF-07265807 can be used for researching anticancer.
  • HY-162085
    Axl-IN-17
    		Inhibitor
    Axl-IN-17 (compound 13c) is an orally active, selective AXL inhibitor with an IC50 value of 3.2 nM. Axl-IN-17 reveals antitumor efficacy.